secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2022-11-17T23:59:59+00:00
Accession:  0001213900-22-073492
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed terminates interim CFO Brenda Edwards; promotes Sarah Li to VP Accounting and Controller
--------------------------------------------------------------------------------

- Brenda Edwards' consulting agreement terminated effective Nov 20, 2022; she served as interim CFO since April 2022.
- Sarah Li promoted to VP of Accounting and Controller and Principal Accounting Officer; she was Controller since Jan 2020.
- Company in discussions to engage new interim financial leadership (CFO) consulting services.
- Press release issued Nov 17, 2022 providing management change update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/ea168928-8k_inmedpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-073492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer